



*Formerly known as The International Symposium on Regional Cancer Therapies*

The SSO Advanced Cancer Therapies Committee invites you to submit your abstracts for the **SSO Advanced Cancer Therapies**, taking place **February 18 – 20, 2023** at the Rancho Bernardo Inn, San Diego, CA.

The committee encourages both SSO members and surgeons involved in cancer care to submit their work and make this the best Symposium yet.

[Call for Abstracts will be open August 1, 2022](#)

#### Key Dates:

- **ABSTRACT DEADLINE:** October 3, 2022 at 11:59 pm ET. *\*No extensions will be granted*
- **ABSTRACT NOTIFICATIONS:** Sent by end of October 2022
- **ABSTRACT WITHDRAWAL DEADLINE:** November 28, 2022

#### Abstract Submission Website:

<https://www.abstractscorecard.com/cfp/submit/login.asp?EventKey=BNZOSNHX>

#### Abstract Categories include:

- Peritoneal Metastases
- HPB
- Applied Research
- Limb/Sarcoma/Melanoma
- Clinical Trials
- Gynecologic Oncology
- Other (please specify)

#### SUBMIT YOUR SCIENTIFIC RESEARCH TO ACT 2023

As you prepare your submission to the Meeting, please make note of the following details:

- Abstracts submitted for presentation at SSO 2023 will be allowed to be presented at this meeting as well. You will not be penalized for submitting to and/or presenting at both events and are encouraged to do so!
- No submission extensions will be granted.
- The SSO has enacted a \$60.00 submission fee for each abstract submitted for consideration to ACT 2023. The submission fee must be paid via credit card when submitting your abstract. If the fee is not paid, the abstract will not be considered as “submitted”. There is no additional charge for revising a submitted abstract.
- Abstracts may ONLY be submitted online.
- There are no restrictions on the number of abstracts you may submit.
- Science only! Abstracts may NOT be about products or lines of business.
- All reviewers, session planners and invited faculty will be required to disclose all financial relationships through the online system, helping to ensure high-quality, unbiased presentations and compliance with CME regulations. In addition, all authors must disclose all financial relationships during the submission process before their abstract will be considered and reviewed.
- There is a limit of 20 co-authors for each abstract.
- Posters will be in an electronic format
- Submission of an abstract does not constitute registration for the meeting. Presenters and authors of accepted abstracts attending the meeting are expected to register and pay the meeting registration fee.

All abstract presentations will be in-person only. Registration and housing information will be available on the website in October.

- **Types of abstracts accepted: Oral Presentations, ePoster Presentations and ePoster only.**
- Please make sure you have your complete abstract and author information.

### ACCEPTED ABSTRACTS & THE *ANNALS OF SURGICAL ONCOLOGY*

SSO leadership believes that research presented at the International Conference on Surgical Cancer Care should be published in the *Annals of Surgical Oncology* (ASO), the official journal of the SSO. The following guidance provides submission information; detailed information will be provided to accepted abstract presenters.

Presenters of abstracts accepted for the Advanced Cancer Therapies are encouraged to submit their manuscripts to the ASO as well. Publication of all manuscripts in the journal is subject to the ASO peer review process.

Detailed information will be provided after acceptances are sent out.

### SUBMISSION REQUIREMENTS

As you prepare your abstract submission to the Meeting, please make note of the following requirements and instructions.

- **Character Limit:** There is a limit of 2,300 characters for the text of your abstract submission. This includes the title and abstract body, including all spaces. If you copy and paste the title and/or body from your word processor, most special characters will transfer. You can replace special characters and/or insert formatting tags using the character palette.
- **Title:** The title should be entered in mixed case (upper and lower-case letters). DO NOT enter the title in all capital or all lower-case letters. Do not use formatting tags. The title will be formatted automatically by the system at the time of print production. Abbreviations must not be used in the title. Use generic product names in the title. Titles with product/brand names will disqualify the abstract.
- **Abstract Body:** Include the following:
  - **INTRODUCTION:** The introduction should be 2 or 3 brief sentences describing the objectives of the study.
  - **METHODS:** A description of the methods used to conduct the study must be included (i.e., retrospective chart review, prospective trial). Detailed descriptions of laboratory techniques should not be included (i.e., measurements were made of calcium, phosphate and creatinine). Do not mention the institution where the work was performed in the body or title of the abstract.
  - **RESULTS:** The results should occupy one-half to two-thirds of the abstract, and specific data necessary to evaluate the abstract should be included. If there is concern that additional data would enhance the abstract, then please strongly consider including it. Statements such as "data will be discussed at the presentation" are grounds for disqualification.
  - **CONCLUSIONS:** The conclusion should be no more than 2 or 3 sentences regarding the significance of the results in the context of the original objectives.
- **Learning Objective:** Your learning objective should be a clear, concise statement of what participants should be able to do as a result of the CME activity.
- **Table or Image:** You may add **one table OR one image** to your Oral or ePoster abstract (not both). Characters will not be deducted from the total character count for tables and images. Tables and Images can be easily edited or deleted any time before the submission deadline.
- **Presentation Type:** You may select one of the following options when submitting your abstract: Accept for Either Oral or Poster; Oral Presentation Only; Poster Only.
- **Category:** It is *extremely important* that you properly categorize your abstract so that it will go to the appropriate review group.
- **Authors:** Please enter all authors and their locations (including yourself) in the order they should appear in the heading of the abstract. All authors must be listed with full first name, middle initial, last name and degree. **Your name is defaulted as the presenter and first author.** Please adjust if this is incorrect. Full instructions are listed on the submission site.
- **Disclosure, Release and IRB Approvals:** The SSO requires each lead author to provide a Presenter Release, Institutional Review Board (IRB) approval (if applicable), and disclosure of financial relationships. All authors and presenters must disclose all financial relationships with any ineligible companies that have occurred within the past 24 months and acknowledge any support from ineligible companies for studies relating to the abstract. Please refer to the Conflict of Interest Policy listed on Page

6 below. All authors and co-authors must agree with the abstract content to be considered for presentation. Please refer to specific requirements in the submission process.

- **Abstract Revisions:** You can edit your abstract on the submission website before the deadline. Once the submission deadline has passed, typos or spelling corrections are the only permitted changes to the abstract text.

## ePoster Instructions

**All posters will be presented on an ePoster monitor – no physical printed poster will be displayed.**

### ePoster Guidelines

ePoster presentations are meant to highlight compelling visual features such as images that you would not otherwise be able to do in the traditional format. When preparing your presentation, please keep the following things in mind:

### Preparing the Presentation

- All ePosters must be created using PowerPoint and can be saved and uploaded as a PDF.
- ePosters format should be ONE static single slide in PPT or single page in PDF
- Aspect Ratio for all ePosters is 16:9.
- There will be two ePoster stations for attendees to view the online poster gallery.
- Highly scored posters will be invited to present a 5-minute poster presentation. Your acceptance letters will specify if your poster is ePoster only, or ePoster with presentation.
- Date and time of poster presentations will be sent in late November.
- ePoster only acceptances will be required to upload their final poster. Attendees will have access to the online poster gallery for 30 days. The ePoster gallery will also be available onsite at the ePoster Stations.
- Accepted ePosters will receive more instructions in November.

## ACPMP Travel Awards

Through the generosity of ACPMP (Appendix Cancer/Pseudomyxoma Peritonei Research Foundation), SSO is offering travel awards of \$1,000 to the highest scoring abstracts in the content/research areas of appendix cancer, pseudomyxoma peritonei, peritoneal surface malignancies/peritoneal carcinomatosis, and/or HIPEC. Abstracts will be reviewed (blinded) by the ACT Program Committee and recipients will be selected based on both the quality of the abstract and the relevance to the content area. Please ensure to check the corresponding question in your submission to be considered for this travel award opportunity. Award winners must register for the meeting and attend in-person. This award covers any travel costs for attending.

Award winners will be notified by December.

## ABSTRACT SELECTION PROCESS & PRESENTATIONS

All abstracts are subject to a blind peer-review by members of the Advanced Cancer Therapies Committee. The committee makes all final decisions relative to the abstract selection and scheduling.

All reviewers, session planners and invited faculty will be required to disclose all financial relationships through the online system, helping to ensure high-quality, unbiased presentations and compliance with CME regulations. In addition, all authors must disclose all financial relationships during the submission process before their abstract will be considered and graded.

## ABSTRACT NOTIFICATIONS

Each abstract submitter will receive an email acknowledging receipt of the abstract after initiating a submission and after completing a submission. If the abstract is selected for inclusion during ACT 2023, the presenting author listed will receive an invitation to participate from the Program Committee by November 2022. If the abstract is not selected, the submitting author will receive a communication regarding its decision by November 2022.

If a first author/presenter chooses to withdraw his or her abstract for any reason, a request must be submitted by **Friday, November 28, 2022**. Any abstract withdrawal requests received after this date will be considered on a case-by-case basis and cannot be assured removal from the Abstract edition of the *Annals of Surgical Oncology* or meeting materials.

## CONFLICT OF INTEREST POLICY

As required by the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all planners, reviewers, presenters, instructors, moderators, authors, and other individuals in a position to control or influence the content of an activity must disclose **ALL** financial relationships with any ineligible company that have occurred within the past **24 months**. **Ineligible companies are those that cannot be accredited in the ACCME System and whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.**

Per ACCME, there is no minimum financial threshold for financial relationships; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose regardless of their view of the relevance of the relationship to the education.

As the accredited provider, SSO is responsible for identifying relevant financial relationships between individuals in control of educational content and ineligible companies and managing these to ensure they do not introduce commercial bias into the education. Financial relationships of any dollar amount are defined as relevant if the educational content is related to the business lines or products of the ineligible company.

All identified conflicts of interest must be resolved, and the educational content vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. Learners must be informed that all relevant financial relationships have been mitigated prior to engaging in accredited education. Learners must also be informed when off label; experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

SSO requires all learners receive disclosure information before engaging in accredited education. Disclosure to learners must include:

- The first and last name of individual with the financial relationship.
- The names of the ineligible companies with which they have relationships.
- The nature of the relationships.
- A statement that all relevant financial relationships have been mitigated.

Disclosure to learners must not include ineligible companies' corporate or product logos, trade names, or product group messages.

SSO must inform learners about planners, faculty, and others in control of content (either individually or as a group) with no relevant financial relationships with ineligible companies.

*Companies that are ineligible to be accredited in the ACCME System (ineligible companies) are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. ACCME does not consider providers of clinical service directly to patients to be ineligible.*

## FURTHER QUESTIONS?

If you have any questions regarding the Call for Abstracts or this event, please call the SSO Education department during business hours at 847-427-1400, or email [advancedtherapies@surgonc.org](mailto:advancedtherapies@surgonc.org).

Technical questions or problems with the system should be directed to the CadmiumCD Support Team. They can be reached by clicking the "Technical Support" link at the top right-hand corner of the submission screen or by emailing [Support@cadmiumcd.com](mailto:Support@cadmiumcd.com). Please be sure your message contains your name, phone, email and an explanation of the problem. Tech Support is available from Monday at 9:00 am through 9:00 pm Friday, EST.